The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 25, 1994

Filed:

Dec. 09, 1992
Applicant:
Inventors:

Daniel J Capon, Hillsborough, CA (US);

Arthur Weiss, Mill Valley, CA (US);

Brian A Irving, San Francisco, CA (US);

Margo R Roberts, San Francisco, CA (US);

Krisztina Zsebo, Woodside, CA (US);

Assignees:

Cell Genesys, Inc., Foster City, CA (US);

The Regents of the University of California, Oakland, CA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07H / ; A61K / ; C12P / ; C07K / ;
U.S. Cl.
CPC ...
536 234 ; 435-6 ; 435 691 ; 4352402 ; 4352401 ; 4353201 ; 435235 ; 536 231 ; 536 235 ; 536 2351 ; 536 2352 ; 536 2353 ; 530350 ; 5303871 ; 5303873 ; 5303877 ; 5303879 ; 5303881 ;
Abstract

Chimeric proteins and DNA sequence encoding chimeric proteins are provided, where the chimeric proteins are characterized by an extracellular domain capable of binding to a ligand in a non-MHC restricted manner, a transmembrane domain and a cytoplasmic domain capable of activating a signaling pathway. The extracellular domain and cytoplasmic domain are not naturally found together. Binding of ligand to the extracellular domain results in transduction of a signal and activation of a signaling pathway in the cell, whereby the cell may be induced to carry out various functions relating to the signalling pathway. A wide variety of extracellular domains may be employed as receptors, where such domains may be naturally occurring or synthetic. The chimeric DNA sequences may be used to modify lymphocytes as well as hematopoietic stem cells as precursors to a number of important cell types.

Published as:
CA2074825A1; WO9210591A1; AU9172291A; NO923171D0; NO923171L; EP0517895A1; KR927003847A; JPH05504262A; EP0517895A4; AU643109B2; US5359046A; EP0732402A2; EP0517895B1; ATE145428T1; DE69123241D1; ES2096749T3; DK0517895T3; DE69123241T2; EP0732402A3; GR3022538T3; KR100246529B1; NO308618B1; JP3242916B2; CA2074825C;

Find Patent Forward Citations

Loading…